Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Duchenne Muscular Dystrophy (DMD)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shanghai Children's Medical Center, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Winston Town) · Winston.town@spotbiosystems.com · 212-920-5501
Contact: Principal Investigator (Wang Jiwen)

Study leads

Wang Jiwen
Principal Investigator
Shanghai Children's Medical Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

Duchenne Muscular Dystrophy (DMD)

Abroad (travel likely)RecruitingPHASE1

Nashville, United States

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Abroad (travel likely)RecruitingPHASE1

Little Rock, United States · Davis, United States

Trial of Cell Based Therapy for DMD

Duchenne Muscular Dystrophy

Abroad (travel likely)RecruitingPHASE1

Minneapolis, United States

Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD)

Abroad (travel likely)RecruitingEARLY_PHASE1

Shanghai, China